The merger has fortified Sun Pharma's position.
Financial pressure on the parent company triggered the move.
These two are now among India's most valuable business houses, ahead of older and more diversified groups, such as the Bajaj, OP Jindal, Anil Ambani, UB, Godrej and Hinduja.
The Indian pharmaceutical players have the potential to corner about 25 per cent of the generic market amounting to $3.75 billion by 2007-08 through leveraging their low cost and technology advantage, according to Rabo India Finance report.
'In terms of a great first year, it was an amazing summer and hopefully, I can better that this time... Hopefully, against a side like India, testing yourself against one of the best bowling attacks in world cricket at the moment'
Lupin will be launching the generic version of Yasmin, a brand of Bayer Healthcare.
Drug major Ranbaxy Laboratories on Thursday said it plans to launch more generic products in the US market with possible marketing exclusivity, while keeping options open for overseas acquisitions to grow its business in various global markets.
It is the first time that the JMI has been placed among the top 10 universities in the (HRD) Ministry's National Institutional Ranking Framework rankings.
It was in 2005, India changed its patent law and started granting patents in medicines.
'OPS did not back off.' 'He wanted transparency and he got it.'
Demand will boom in the US and China, but exporters say it will be difficult for India to tap these markets.
US election results may not reverse Indian markets' bearish trend, says Devangshu Datta
The Ranbaxy experience has made multinational corporations more cautious about Indian acquisitions in general
In 2012, drugs worth $35 billion went off-patent in the US, while the market size of drugs which will see patent expiry in 2013 will halve to $17 billion.
This was not Sharad Pawar or Prithviraj Chavan speaking. It was Uddhav Thackeray, the undisputed chief of the Shiv Sena!
Indian government has set up a panel to fix prices of patented drugs in the country.
Sun Pharmaceutical Industries Ltd Chairman Dilip Shanghvi said he expects Ranbaxy Laboratories Ltd to become profitable in the short term.
'I was in awe of how committed Kareena was, even at this stage of her career.' 'She is so motivated, giving it her all. 'It was very inspiring and motivating, not just for me, but for everyone else to pull up their socks and give it their all.'
Ranbaxy Laboratories Ltd, which has profited handsomely by selling generic drugs in the United States, said on Tuesday it would increase its R&D spending by about 60 per cent over the next five years.
A brand mascot personifies the brand very effectively. They have the capacity to create a better brand recall and strong positioning for a brand. Take this quiz to find out if these mascot have managed to leave a lasting impression.
The challenge of merging Ranbaxy into the company has not been factored in.
Free Basics offers a limited version of the Internet on mobile phones.
What sold the most this year? Beauty, toys and baby care, sports and fitness, television and large appliances, followed by fashion, says T E Narasimhan.
The founders of Gland Pharma, led by Ravi Penmetsa, and KKR, together own 96 per cent of the company.
Global companies, e-commerce platforms and software product firms all want skilled digital workers.
The order, a "negative" overall, will be a short term positive for corporate focused state-run and private lenders because of the possibility of delaying incremental stressed asset recognition.
Basic Customs Duty is being reduced to 2.5 per cent for the equipments required for setting up or substantial expansion of iron ore pellet plants & iron ore beneficiation plants.
Netmeds is looking at using new technologies such as deep learning and data analytics to improve forecasting in terms of the demand of the products for pharma companies, reports Peerzada Abrar.
DRL launched four new products in North America during the previous quarter.
The deal had separately come under scanner of the market regulator Sebi for alleged insider trading violations and the present 'no-objection' from the exchanges.
Mylan had sued the United States Food and Drugs Administration for providing the exclusive right to Ranbaxy, alleging the permission was given on the basis of 'falsified data'.
Rs 1,965-cr deal helps it rake in 3.5 times its investment within four years.
India has a huge trade surplus with US - over $20 billion a year in the past five years.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances